PERSPECTA

News from every angle

← Back to headlines

AbbVie Raises 2026 Outlook Driven by Skyrizi and Rinvoq

AbbVie has increased its 2026 outlook, with strong sales of Skyrizi and Rinvoq offsetting the decline in Humira sales.

PostShare

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

seeking-alphaafr126d ago

AbbVie hikes 2026 outlook as Skyrizi, Rinvoq offset Humira slump

Read full article →

Related Stories

Berkshire Hathaway Signals Long-Term Commitment to Japanese Trading Houses

28m ago

US Commerce Department Signals Reconciliation With AI Firm Anthropic

1h ago

Oil Prices Hold Near $95 Amid Escalating U.S.-Iran Military Tensions

1h ago

Uber Cuts Over 3,000 Jobs in Global Restructuring Push

1h ago